Article Sidebar

Download
PDF
Statistic
Read Counter : 49 Download : 11

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background: The global burden of drug-resistant tuberculosis (DR-TB) has emerged as a significant public health challenge, necessitating the development and use of effective treatment regimens. Linezolid, an oxazolidinone antibiotic, has shown promise in the management of DR-TB due to its ability to inhibit the growth of mycobacteria that are resistant to traditional anti-TB drugs. However, its use has been associated with several adverse effects, one of which is toxic optic neuropathy (TON). Objective: This study aims to investigate the development of toxic optic neuropathy induced by linezolid in patients with drug-resistant tuberculosis. Method: We report a case of a patient with drug-resistant tuberculosis who received linezolid therapy. The reported side effect was the onset of toxic optic neuropathy symptoms. Result: There are two MDR-TB patients who received linezolid therapy. Both patients have been undergoing treatment for one year. They reported complaints of blurred vision after nearly one year of receiving linezolid therapy. Visual acuity tests showed values of up to 2/60 in both eyes. Fundus photographs depict the condition of the patients' eyes, showing vision problems due to defects in the visual field and possible abnormalities in the macula and optic nerve head. Conclusion: There was a disturbance in visual function after undergoing treatment for resistant tuberculosis (TB-RO). Linezolid, which is part of this treatment regimen, is strongly suspected to be the cause of the side effect known as toxic optic neuropathy (TON). Visual acuity improved again after the linezolid therapy was discontinued. The mechanism by which linezolid causes TON is likely related to mitochondrial dysfunction, disruption of blood flow to the optic nerve, and nutritional factors.

Keywords

DR-TB, linezolid, mitochondrial dysfunction, toxic optic neuropathy, visual acuity.

Article Details

References

  1. Bano, S., Nawaz, A., Numan, A., Hassan, M. A., & Shafique, M. B. A. (2022). A Case Report and Literature Review of the Outcome of Linezolid- Induced Optic and Peripheral Neuropathy in Patients With Multidrug-Resistant Pulmonary TB. Frontiers in Neurology, 13. doi: 10.3389/fneur.2022.908584
  2. Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E.,
  3. Moreira, J., Timm, J., McHugh, T. D., Wills, G. H.,
  4. Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., & Spigelman, M. (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 382(10), 893– 902. doi: 10.1056/NEJMOA1901814
  5. De Vriese, A. S., Van Coster, R., Smet, J., Seneca, S., Lovering, A., Van Haute, L. L., Vanopdenbosch, L. J., Martin, J. J., Ceuterick-De Groote, C., Vandecasteele, S., & Boelaert, J. R. (2016). Linezolid-induced inhibition of mitochondrial protein synthesis. Clinical Infectious Diseases, 42(8), 1111–1117. doi: 10.1086/501356
  6. Hirano, M., Palenzuela, L., Hahn, N. M., Nelson, R. P., Arno, J. N., Schobert, C., Bethel, R., Ostrowski, L. A., Sharma, M. R., Datta, P. P., Agrawal, R. K., & Schwartz, J. E. (2015). Does Linezolid Cause Lactic Acidosis by Inhibiting Mitochondrial Protein Synthesis? Clinical Infectious Diseases, 40(12), e113–e116. doi: 10.1086/430441
  7. Kardani, S., Hadia, R., Shah, A., Parmar, G., Maheshwari, R., Seth, A., Rathod, T., & Joshi, D. (2021). A Case Report on Reversible Toxic Optic Neuropathy on Long Term Treatment of Linezolid in Extensively Drug-Resistant Tuberculosis Patient. Journal of Pharmaceutical Research International, 33(37A), 7–11. doi: 10.9734/jpri/2021/v33i37A31972
  8. Kemenkes RI. (2023). Dashboard Data Kondisi TBC di Indonesia. Retrieved from https://tbindonesia.or.id/pustaka-tbc/dashboard/
  9. Lee, S., Kang, B. H., Ryu, W. Y., Um, S. J., Roh, M. S., &
  10. Son, C. (2018). Is Severe and Long-lasting Linezolid-induced Optic Neuropathy Reversible? Internal Medicine (Tokyo, Japan), 57(24), 3611–
  11. doi: 10.2169/internalmedicine.1344-18
  12. Lifan, Z., Sainan, B., Feng, S., Siyan, Z., & Xiaoqing, L. (2019). Linezolid for the treatment of extensively drug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 23(12), 1293–1307. doi: 10.5588/ijtld.18.0822
  13. Lukitosari, E., Farikha, M., Dewi, R. K., Sulistyo, Oktavina, W., Frasasti, D., Utami, D. H., Purwandini, H. R., Verdinawati, T., Yuliarsih, T., Hariri, A., ANdini, A., Salsabila, A., Nabila, F. A., Isnariani, T. A., Febrina, E., Winarsih, S., Indarwanti, W., Wangge, G., … Ambari, A. M. (2022). Petunjuk Teknis Monitoring dan Manajemen Efek Samping Obat Secara Aktif Pada Pengobatan TBC Resisten Obat di INdonesia (V. G. Clara & Y. Permata (eds.)). Jakarta: Kementerian Kesehatan Republik Indonesia.
  14. Rukmana, A., Karuniawati, A., Sianturi, A., Wihardi, A. P., Kiranasari, A., Yuwono, A., Sinaga, B. Y., Prasetya, D., Novizar, D., Aulia, D., Wulandari, D. A., Frasasti, D., Febrina, E., Burhan, E., Udin, F., & Nabila, F. A. (2020). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia (E. Lukitosari, R. K. Dewi, & Y. Permata (eds.)). Jakarta: Kementerian Kesehatan Republik Indonesia.
  15. Sharma, P., & Sharma, R. (2017). Toxic optic neuropathy. Indian Journal of Ophthalmology, 59(2), 137–141. doi: 10.4103/0301-4738.77035
  16. Spinazzi, M. (2016). Optic Neuropathies Caused by Micronutrient Deficiencies and Toxins. In Handbook of Nutrition, Diet and the Eye. Elsevier. doi: 10.1016/B978-0-12-401717-7.00039-3
  17. Srivastava, A., Kshetrimayum, S., Gupta, S. K., & Kant, S. (2017). Linezolid-induced optic neuropathy in XDR pulmonary TB: A case series. Indian Journal of Tuberculosis, 64(2), 129–133. doi: https://doi.org/10.1016/j.ijtb.2016.11.010
  18. Stacey, A. W., Nagham, A.-Z., Claudia Prospero, P., Nita, B., & Farida, A. B. (2023). Toxic Optic Neuropathy. Retrieved from
  19. https://eyewiki.org/Toxic_Optic_Neuropathy
  20. Toolan, K. J., Fondriest, J., Keenan, K., Mizen, T., &Stosic, M. (2023). Linezolid toxic optic neuropathy: A case report and review of visual prognosis. American Journal of Ophthalmology Case Reports,
  21. doi: 10.1016/j.ajoc.2023.101922
  22. Vallabhaneni, S., Mendonca, T. M., Nayak, R. R., Kamath, G., & Kamath, A. (2023). Linezolid induced toxic optic neuropathy in drug resistant tuberculosis-A case series. Indian Journal of Tuberculosis. doi: 10.1016/j.ijtb.2023.06.016
  23. Wasserman, S., Meintjes, G., & Maartens, G. (2016). Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Review of Anti-Infective Therapy, 14(10), 901–915. doi:
  24. 1080/14787210.2016.1225498
  25. WHO. (2022). WHO consolidated guidelines on tuberculosis. In WHO Press. Geneva.
  26. WHO. (2023). Global Tuberculosis Report 2023. In January. Geneva. Retrieved from https://www.who.int/publications/i/item/978924008 3851